Feinstein Institutes Study Vagus Nerve Stimulation for Obesity Obesity is one of the most pressing health challenges facing the modern world, with over a third of the global population affected…
Innate Pharma Announces First Quarter 2025 Financial Results and Business Highlights Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage oncology-focused biotechnology company pioneering innovative immunotherapies, announced its consolidated…
Ten-Year Data Perjeta Regimen Cuts Death Risk by 17% in HER2+ Breast Cancer In a significant milestone for the treatment of early-stage HER2-positive breast cancer, Genentech, a member of the…
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful…
InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA In a landmark development for China’s oncology therapeutics landscape, InnoCare Pharma Limited (HKEX: 09969; SSE: 688428), a biopharmaceutical company recognized for…
Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile…
Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the…
Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal…
Global pharmaceutical major Lupin Limited announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy…
Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership…